Diabetes Mellitus Type 2IMSTNCT06936670
Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes
A study testing Inspiratory Muscle Strength Training (IMST) in people with Diabetes Mellitus Type 2, run by Seattle Children's Hospital at 2 sites in United States.
Trial summary
High-resistance, short-duration inspiratory muscle strength training (IMST) is a novel lifestyle intervention involving 30 inhalations against a resistive load which requires only ~5 min/day and is thus ideal for youth with T2D (Y-T2D). Read more about this study
- Who is it for?
- Ages 14 to 40 years
- Conditions the study is for
- Diabetes Mellitus Type 2
- What is being tested?
- Inspiratory Muscle Strength Training (IMST)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 2 sitesUnited States
- Study dates
- 30 Apr 2025to 28 Feb 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 40 years
- All sexes
- No healthy volunteers
- Child, Adult
Inclusion Criteria: Aged 14-40, have had T2D for a least one year, HbA1C less than 12%.
-
Exclusion Criteria: Have had type II diabetes for more than 18 years, estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2 or Albumin-to-creatinine ratio (ACR) greater than 2200mg/g, blood pressure greater than 160/100 mm Hg.
-
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Seattle Children's Hospital
Seattle, Washington, 98102
Kalie Tommerdahl, 206-616-9015, ktomme@uw.edu
Kalie Tommerdahl, MD
- Not yet recruiting
University of Washington Medicine Diabetes Institute
Seattle, Washington, 98109
Kalie Tommerdahl, MD, 206) 616-9015, ktomme@uw.edu
Kalie Tommerdahl, MD
About this study
High-resistance, short-duration inspiratory muscle strength training (IMST) is a novel lifestyle intervention involving 30 inhalations against a resistive load which requires only ~5 min/day and is thus ideal for youth with T2D (Y-T2D). Investigators seek to 1: assess changes in casual and 24-hr SBP, endothelial function, and arterial stiffness after 3 months of IMST vs. sham training in Y-T2D, 2: Define changes in eGFR andalbuminuria after 3 months of IMST vs. sham in Y-T2D, 3: Interrogate mechanisms of IMST by translational assessments of NO bioavailability, endothelial NO synthase (eNOS) activation, and ROS/oxidative stress, and determine the role of circulating factors.
- Conditions
- Diabetes Mellitus Type 2
- Being tested
- Inspiratory Muscle Strength Training (IMST), Sham Training
- Keywords
- Type 2 Diabetes, Inspiratory Strength Training, Blood Pressure, Kidney Health, Cardiovascular Function, Diabetic Kidney Disease
- Medical subject headings
- Diabetes Mellitus, Type 2, Diabetic Nephropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inspiratory Muscle Strength Training (IMST)Device
A novel form of physical training that uses the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device, generating large negative intrathoracic pressures. The device can be set to different levels of resistance, meaning the intervention and sham groups will undergo the same training, but at 75% and 15% of their maximal inspiratory pressure respectively.
Sham TrainingDevice
The same training regiment but at much lower resistance, offering little to strength training impact.
| Study group | Role | What they receive |
|---|---|---|
| IMST | Experimental | Using the POWERBreathe pressure threshold training device, participants will perform 30 inspiratory maneuvers (5 sets of 6, 1 min rest) 6 days/week for 3 months. This is an over the counter product that will be used according to its instructions. The IMST group will train at 75% maximal inspiratory pressure. Receives: Device: Inspiratory Muscle Strength Training (IMST) |
| Sham/Placebo | Sham comparator | Using the POWERBreathe pressure threshold training device, participants will perform 30 inspiratory maneuvers (5 sets of 6, 1 min rest) 6 days/week for 3 months. This is an over the counter product that will be used according to its instructions. The Sham group will train at 15% maximal inspiratory pressure. Receives: Device: Sham Training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic Blood Pressure
Measures of casual clinic and 24-hour ambulatory blood pressure monitoring
Measured: 3 months
Secondary outcomes (4)
Endothelial function
Measured by brachial artery flow-mediated dilation and endothelial cell collection and analysis.
Measured: 3 months
Arterial stiffness
Measured by carotid-femoral pulse-wave velocity and carotid-radial pulse-wave analysis using a SphygmoCor.
Measured: 3 months
Kidney Function
Measured by estimated glomerular filtration rate and albuminuria assessments
Measured: 3 months
Body Composition
Measured by BIS (Bioimpedance spectroscopy)
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2025
- Study start30 Apr 2025
- Primary completion28 Feb 2026 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seattle Children's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Washington
- Responsible party
- Principal investigator, Kalie Tommerdahl, Seattle Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06936670
- Sponsor's protocol ID
- STUDY00005096
- Acronym
- IMST
- Status last verified
- Jun 2025
- First submitted
- 14 Apr 2025
- Last updated
- 13 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided